UNSPSC 51432506: Trandolaprilat

This classification denotes an ace inhibitor with the molecular formula C22H30N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RR6866VL0O, chemically known as 1h-indol-2-carboxylic acid, 1-(2-((1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)octahydro- but generally known as trandolaprilat, which bears US NIH Compound Identifier 128549. European Medicines Agency schedules Trandolaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11213MIG.

UNSPSC 51432506 Trandolaprilat is a Commodity code representing individual pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and multistate cooperative purchasing agreements. Recent solicitations show state and local buyers acquiring this medication—along with other emergency pharmaceuticals and generic drugs—through competitive sealed bids, requests for proposal, and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. The work involves supplying FDA-compliant medications with specified shelf lives, expiration warranties, and delivery schedules, often bundled with safety documentation, accessibility certifications, and compliance attestations covering manufacturing practices and drug supply chain security.

Activity in this code spans fire rescue services, state health and human services agencies, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (including similar emergency drugs) with an estimated value of $40,000 and a response deadline of April 8, 2026; the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, distributed through authorized wholesalers across participating states including Oregon. Geographic activity centers on Florida, Texas, and Minnesota-led cooperative purchasing, with the cooperative model reaching additional member jurisdictions. The code shows modest but recurring activity driven by standing demand from emergency services and multistate health purchasing, with response windows typically measured in weeks to a few months and contract terms ranging from one to two years with renewal options.